|
Gene: SLC18A2 |
Gene summary for SLC18A2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SLC18A2 | Gene ID | 6571 |
Gene name | solute carrier family 18 member A2 | |
Gene Alias | PKDYS2 | |
Cytomap | 10q25.3 | |
Gene Type | protein-coding | GO ID | GO:0001504 | UniProtAcc | Q05940 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6571 | SLC18A2 | CA_HPV_1 | Human | Cervix | CC | 2.03e-21 | -6.02e-01 | 0.0264 |
6571 | SLC18A2 | CA_HPV_3 | Human | Cervix | CC | 1.46e-03 | -3.85e-01 | 0.0414 |
6571 | SLC18A2 | N_HPV_2 | Human | Cervix | N_HPV | 1.54e-08 | -5.13e-01 | -0.0131 |
6571 | SLC18A2 | CCI_1 | Human | Cervix | CC | 1.05e-04 | -7.32e-01 | 0.528 |
6571 | SLC18A2 | CCI_2 | Human | Cervix | CC | 1.41e-02 | -6.88e-01 | 0.5249 |
6571 | SLC18A2 | CCI_3 | Human | Cervix | CC | 3.17e-05 | -7.16e-01 | 0.516 |
6571 | SLC18A2 | CCII_1 | Human | Cervix | CC | 2.80e-08 | -7.21e-01 | 0.3249 |
6571 | SLC18A2 | Tumor | Human | Cervix | CC | 4.93e-29 | -7.32e-01 | 0.1241 |
6571 | SLC18A2 | sample1 | Human | Cervix | CC | 3.97e-08 | -7.32e-01 | 0.0959 |
6571 | SLC18A2 | sample3 | Human | Cervix | CC | 7.30e-28 | -7.32e-01 | 0.1387 |
6571 | SLC18A2 | H2 | Human | Cervix | HSIL_HPV | 3.77e-25 | -7.27e-01 | 0.0632 |
6571 | SLC18A2 | L1 | Human | Cervix | CC | 3.88e-11 | -7.32e-01 | 0.0802 |
6571 | SLC18A2 | T1 | Human | Cervix | CC | 2.47e-19 | -7.32e-01 | 0.0918 |
6571 | SLC18A2 | T2 | Human | Cervix | CC | 7.21e-04 | -7.32e-01 | 0.0709 |
6571 | SLC18A2 | T3 | Human | Cervix | CC | 4.34e-27 | -7.32e-01 | 0.1389 |
6571 | SLC18A2 | EOLP-1 | Human | Oral cavity | EOLP | 2.85e-13 | 5.14e-01 | -0.0202 |
6571 | SLC18A2 | EOLP-2 | Human | Oral cavity | EOLP | 4.55e-21 | 7.34e-01 | -0.0203 |
6571 | SLC18A2 | NEOLP-1 | Human | Oral cavity | NEOLP | 3.66e-03 | 3.16e-01 | -0.0194 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190342611 | Cervix | N_HPV | regulation of reactive oxygen species biosynthetic process | 6/534 | 52/18723 | 3.50e-03 | 2.83e-02 | 6 |
GO:005123525 | Oral cavity | EOLP | maintenance of location | 75/2218 | 327/18723 | 1.04e-08 | 4.98e-07 | 75 |
GO:000979121 | Oral cavity | EOLP | post-embryonic development | 23/2218 | 80/18723 | 3.53e-05 | 4.91e-04 | 23 |
GO:200037725 | Oral cavity | EOLP | regulation of reactive oxygen species metabolic process | 35/2218 | 157/18723 | 1.51e-04 | 1.62e-03 | 35 |
GO:007259323 | Oral cavity | EOLP | reactive oxygen species metabolic process | 48/2218 | 239/18723 | 1.62e-04 | 1.70e-03 | 48 |
GO:00019754 | Oral cavity | EOLP | response to amphetamine | 11/2218 | 33/18723 | 1.01e-03 | 7.54e-03 | 11 |
GO:00990035 | Oral cavity | EOLP | vesicle-mediated transport in synapse | 39/2218 | 200/18723 | 1.14e-03 | 8.29e-03 | 39 |
GO:000963625 | Oral cavity | EOLP | response to toxic substance | 48/2218 | 262/18723 | 1.37e-03 | 9.49e-03 | 48 |
GO:00995044 | Oral cavity | EOLP | synaptic vesicle cycle | 34/2218 | 181/18723 | 4.25e-03 | 2.33e-02 | 34 |
GO:20003781 | Oral cavity | EOLP | negative regulation of reactive oxygen species metabolic process | 13/2218 | 52/18723 | 6.47e-03 | 3.18e-02 | 13 |
GO:19034271 | Oral cavity | EOLP | negative regulation of reactive oxygen species biosynthetic process | 7/2218 | 21/18723 | 8.36e-03 | 3.91e-02 | 7 |
GO:00140756 | Oral cavity | EOLP | response to amine | 12/2218 | 49/18723 | 1.03e-02 | 4.64e-02 | 12 |
GO:000963633 | Oral cavity | NEOLP | response to toxic substance | 56/2005 | 262/18723 | 3.13e-07 | 9.85e-06 | 56 |
GO:000979131 | Oral cavity | NEOLP | post-embryonic development | 24/2005 | 80/18723 | 1.88e-06 | 4.50e-05 | 24 |
GO:005123531 | Oral cavity | NEOLP | maintenance of location | 62/2005 | 327/18723 | 5.41e-06 | 1.12e-04 | 62 |
GO:007259332 | Oral cavity | NEOLP | reactive oxygen species metabolic process | 46/2005 | 239/18723 | 5.77e-05 | 7.77e-04 | 46 |
GO:200037731 | Oral cavity | NEOLP | regulation of reactive oxygen species metabolic process | 30/2005 | 157/18723 | 1.18e-03 | 8.72e-03 | 30 |
GO:000197512 | Oral cavity | NEOLP | response to amphetamine | 9/2005 | 33/18723 | 6.45e-03 | 3.32e-02 | 9 |
Page: 1 2 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501220 | Cervix | CC | Parkinson disease | 102/1267 | 266/8465 | 1.81e-21 | 1.47e-19 | 8.66e-20 | 102 |
hsa05012110 | Cervix | CC | Parkinson disease | 102/1267 | 266/8465 | 1.81e-21 | 1.47e-19 | 8.66e-20 | 102 |
hsa0501225 | Cervix | HSIL_HPV | Parkinson disease | 43/459 | 266/8465 | 6.69e-11 | 6.53e-09 | 5.28e-09 | 43 |
hsa0501235 | Cervix | HSIL_HPV | Parkinson disease | 43/459 | 266/8465 | 6.69e-11 | 6.53e-09 | 5.28e-09 | 43 |
hsa0501244 | Cervix | N_HPV | Parkinson disease | 45/349 | 266/8465 | 1.93e-16 | 1.75e-14 | 1.37e-14 | 45 |
hsa0501254 | Cervix | N_HPV | Parkinson disease | 45/349 | 266/8465 | 1.93e-16 | 1.75e-14 | 1.37e-14 | 45 |
hsa0501245 | Oral cavity | EOLP | Parkinson disease | 75/1218 | 266/8465 | 2.26e-09 | 5.62e-08 | 3.32e-08 | 75 |
hsa0472812 | Oral cavity | EOLP | Dopaminergic synapse | 33/1218 | 132/8465 | 8.18e-04 | 3.04e-03 | 1.79e-03 | 33 |
hsa0501255 | Oral cavity | EOLP | Parkinson disease | 75/1218 | 266/8465 | 2.26e-09 | 5.62e-08 | 3.32e-08 | 75 |
hsa0472813 | Oral cavity | EOLP | Dopaminergic synapse | 33/1218 | 132/8465 | 8.18e-04 | 3.04e-03 | 1.79e-03 | 33 |
hsa0501262 | Oral cavity | NEOLP | Parkinson disease | 78/1112 | 266/8465 | 1.34e-12 | 1.06e-10 | 6.68e-11 | 78 |
hsa0472821 | Oral cavity | NEOLP | Dopaminergic synapse | 30/1112 | 132/8465 | 1.61e-03 | 7.30e-03 | 4.59e-03 | 30 |
hsa0501272 | Oral cavity | NEOLP | Parkinson disease | 78/1112 | 266/8465 | 1.34e-12 | 1.06e-10 | 6.68e-11 | 78 |
hsa0472831 | Oral cavity | NEOLP | Dopaminergic synapse | 30/1112 | 132/8465 | 1.61e-03 | 7.30e-03 | 4.59e-03 | 30 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC18A2 | SNV | Missense_Mutation | novel | c.340N>A | p.Pro114Thr | p.P114T | Q05940 | protein_coding | tolerated(0.26) | benign(0.062) | TCGA-3C-AALK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
SLC18A2 | SNV | Missense_Mutation | c.475N>A | p.Pro159Thr | p.P159T | Q05940 | protein_coding | tolerated(0.57) | benign(0.015) | TCGA-A8-A09E-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD | |
SLC18A2 | insertion | In_Frame_Ins | novel | c.284_285insGTTCTCAGGGCCGTTGGGGGCATGGTTCTTTCTAGTGAG | p.Asp95delinsGluPheSerGlyProLeuGlyAlaTrpPhePheLeuValSer | p.D95delinsEFSGPLGAWFFLVS | Q05940 | protein_coding | TCGA-A2-A0T2-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | xeloda | PD | ||
SLC18A2 | insertion | Nonsense_Mutation | novel | c.359_360insTAAGTAAAGTG | p.Glu120AspfsTer3 | p.E120Dfs*3 | Q05940 | protein_coding | TCGA-AN-A0FD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
SLC18A2 | SNV | Missense_Mutation | c.1369N>A | p.Gly457Arg | p.G457R | Q05940 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-C5-A1MJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
SLC18A2 | SNV | Missense_Mutation | novel | c.1340N>A | p.Ile447Asn | p.I447N | Q05940 | protein_coding | deleterious(0) | possibly_damaging(0.853) | TCGA-C5-A8XI-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
SLC18A2 | SNV | Missense_Mutation | novel | c.892N>A | p.Ala298Thr | p.A298T | Q05940 | protein_coding | deleterious(0.01) | probably_damaging(0.964) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
SLC18A2 | SNV | Missense_Mutation | novel | c.165N>C | p.Lys55Asn | p.K55N | Q05940 | protein_coding | tolerated(0.5) | benign(0.003) | TCGA-VS-A9V1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
SLC18A2 | SNV | Missense_Mutation | c.815C>A | p.Pro272Gln | p.P272Q | Q05940 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3818-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
SLC18A2 | SNV | Missense_Mutation | c.213N>G | p.Ile71Met | p.I71M | Q05940 | protein_coding | tolerated(0.23) | benign(0.018) | TCGA-AA-3851-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6571 | SLC18A2 | DRUGGABLE GENOME, TRANSPORTER | inhibitor | CHEMBL1201178 | LISDEXAMFETAMINE DIMESYLATE | |
6571 | SLC18A2 | DRUGGABLE GENOME, TRANSPORTER | Lobeline | LOBELINE | ||
6571 | SLC18A2 | DRUGGABLE GENOME, TRANSPORTER | inhibitor | 178101473 | ||
6571 | SLC18A2 | DRUGGABLE GENOME, TRANSPORTER | Alkavervir | ALKAVERVIR | ||
6571 | SLC18A2 | DRUGGABLE GENOME, TRANSPORTER | inhibitor | 178101328 | ||
6571 | SLC18A2 | DRUGGABLE GENOME, TRANSPORTER | bupropion | BUPROPION | 22947179 | |
6571 | SLC18A2 | DRUGGABLE GENOME, TRANSPORTER | NBI-98854 | VALBENAZINE TOSYLATE | ||
6571 | SLC18A2 | DRUGGABLE GENOME, TRANSPORTER | inhibitor | CHEMBL2364639 | VALBENAZINE | |
6571 | SLC18A2 | DRUGGABLE GENOME, TRANSPORTER | AV 133 | |||
6571 | SLC18A2 | DRUGGABLE GENOME, TRANSPORTER | DEXTROAMPHETAMINE | DEXTROAMPHETAMINE |
Page: 1 2 3 4 5 |